Cargando…

A new humanized in vivo model of KIT D816V(+) advanced systemic mastocytosis monitored using a secreted luciferase

Systemic mastocytosis are rare neoplasms characterized by accumulation of mast cells in at least one internal organ. The majority of systemic mastocytosis patients carry KIT D816V mutation, which activates constitutively the KIT receptor. Patient with advanced forms of systemic mastocytosis, such as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bibi, Siham, Zhang, Yanyan, Hugonin, Caroline, Mangean, Mallorie Depond, He, Liang, Wedeh, Ghaith, Launay, Jean-Marie, Van Rijn, Sjoerd, Würdinger, Thomas, Louache, Fawzia, Arock, Michel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347747/ https://www.ncbi.nlm.nih.gov/pubmed/27783996 http://dx.doi.org/10.18632/oncotarget.12824

Ejemplares similares

Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation
por: Zappulla, Jacques P., et al.
Publicado: (2005)

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
por: Arock, Michel, et al.
Publicado: (2018)

Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis
por: Grootens, Jennine, et al.
Publicado: (2019)

Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis
por: Lyberg, Katarina, et al.
Publicado: (2016)

Adverse Prognostic Impact of the KIT D816V Transcriptional Activity in Advanced Systemic Mastocytosis
por: Naumann, Nicole, et al.
Publicado: (2021)

New Approach to Paediatric Mastocytosis: Implications of KIT D816V Mutation Detection in Peripheral Blood
por: CZARNY, Justyna, et al.
Publicado: (2020)

Functional multiplex reporter assay using tagged Gaussia luciferase
por: van Rijn, Sjoerd, et al.
Publicado: (2013)

KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

Case Report: Evolution of KIT D816V-Positive Systemic Mastocytosis to Myeloid Neoplasm With PDGFRA Rearrangement Responsive to Imatinib
por: Sciumè, Mariarita, et al.
Publicado: (2021)

Eosinophilia in a patient with aggressive systemic mastocytosis harboring a KIT D816V mutation: A case report
por: Cao, Lihong, et al.
Publicado: (2023)

CABLES1 Deficiency Impairs Quiescence and Stress Responses of Hematopoietic Stem Cells in Intrinsic and Extrinsic Manners
por: He, Liang, et al.
Publicado: (2019)

Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis
por: Lübke, Johannes, et al.
Publicado: (2019)

KIT D816V Mast Cells Derived from Induced Pluripotent Stem Cells Recapitulate Systemic Mastocytosis Transcriptional Profile
por: de Toledo, Marcelo A. S., et al.
Publicado: (2023)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

P996: UTILITY OF KIT P.D816 IN MYELOID NEOPLASM WITHOUT DOCUMENTED SYSTEMIC MASTOCYTOSIS TO DETECT HIDDEN MAST CELLS IN BONE MARROW
por: Kim, D. H., et al.
Publicado: (2022)

Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2017)

Mastocytosis: a mutated KIT receptor induced myeloproliferative disorder
por: Chatterjee, Anindya, et al.
Publicado: (2015)

Germline mutations of KIT in gastrointestinal stromal tumor (GIST) and mastocytosis
por: Ke, Hengning, et al.
Publicado: (2016)

CXCR4/CXCL12 axis counteracts hematopoietic stem cell exhaustion through selective protection against oxidative stress
por: Zhang, Yanyan, et al.
Publicado: (2016)

CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis
por: Bandara, Geethani, et al.
Publicado: (2023)

Sensitive and reliable detection of Kit point mutation Asp 816 to Val in pathological material
por: Kähler, Christian, et al.
Publicado: (2007)

De novo Leukemic Variant of Mast Cell Leukemia With KIT D816V
por: Bang, Hae In, et al.
Publicado: (2015)

Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia
por: Sandow, Lyndsey, et al.
Publicado: (2023)

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression
por: Verstovsek, Srdan
Publicado: (2013)

Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors
por: Shomali, William, et al.
Publicado: (2021)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
por: Valent, Peter, et al.
Publicado: (2019)

Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis
por: Reszka, Edyta, et al.
Publicado: (2021)

Potent efficacy of chlorpromazine in acute myeloid leukemia harboring KIT-D816V mutation
por: Rai, Shinya, et al.
Publicado: (2021)

Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of Onset
por: Lanternier, Fanny, et al.
Publicado: (2008)

P1049: A PHASE 2 STUDY OF BEZUCLASTINIB (CGT9486), A NOVEL, HIGHLY SELECTIVE, POTENT KIT D816V INHIBITOR, IN ADULTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS (APEX): METHODS, BASELINE DATA, AND EARLY INSIGHTS
por: DeAngelo, D. J., et al.
Publicado: (2022)

Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production
por: Tobío, Araceli, et al.
Publicado: (2020)

Clinical Impact of Inherited and Acquired Genetic Variants in Mastocytosis
por: Nedoszytko, Boguslaw, et al.
Publicado: (2021)

Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond
por: Sprinzl, Bettina, et al.
Publicado: (2021)

Loss of Function of TET2 Cooperates with Constitutively Active KIT in Murine and Human Models of Mastocytosis
por: De Vita, Serena, et al.
Publicado: (2014)

Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy
por: Yang, Min, et al.
Publicado: (2017)

Cisco CCNA/CCENT Exam 640-802, 640-822, 640-816 Preparation Kit: With Cisco Router Simulations
por: Liu, Dale
Publicado: (2009)

The spleen microenvironment influences disease transformation in a mouse model of KIT(D816V)-dependent myeloproliferative neoplasm
por: Pelusi, Natalie, et al.
Publicado: (2017)

Targeting Sphingosine Kinase Isoforms Effectively Reduces Growth and Survival of Neoplastic Mast Cells With D816V-KIT
por: Bandara, Geethani, et al.
Publicado: (2018)

KIT D816V Positive Acute Mast Cell Leukemia Associated with Normal Karyotype Acute Myeloid Leukemia
por: Lopes, Marta, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1m3g6orn4ibsq71j09uoijcapv